Skip to main content
David Iberri, MD, Oncology, Stanford, CA, Stanford Health Care

DavidJosephIberriMD

Oncology Stanford, CA

Medicine Resident, Stanford Hospital & Clinics

Dr. Iberri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Iberri's full profile

Already have an account?

  • Office

    300 Pasteur Dr
    Stanford Medicine Residency Office, Grant S101
    Stanford, CA 94305
    Phone+1 650-498-6000
  • Is this information wrong?

Education & Training

  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2013 - 2016
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2013
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 2010 - 2011
  • University of Vermont College of Medicine
    University of Vermont College of MedicineClass of 2010

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2011 - 2024

Publications & Presentations

PubMed

Abstracts/Posters

  • Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses
    David Iberri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Evaluating Selinexor in Patients with Relapsed/Refractory DLBCL
    Evaluating Selinexor in Patients with Relapsed/Refractory DLBCLSeptember 1st, 2020
  • Has the FDA Been Approving Some Drugs Without Proper Evidence?
    Has the FDA Been Approving Some Drugs Without Proper Evidence?August 20th, 2019

Hospital Affiliations